Experience with cyclosporine in endogenous uveitis posterior

Transplantation Proceedings

Volumn 36, Issue 2 SUPPL., 2004, Pages S372-S377

  Hesselink, D A ^a   Baarsma, G S ^b   Kuijpers, R W A M ^a   Van Hagen, P M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ROTTERDAM EYE HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIFUNGAL AGENT; ANTIHYPERTENSIVE AGENT; AZATHIOPRINE; CARBAMAZEPINE; CHLORAMBUCIL; CLARITHROMYCIN; COLCHICINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOTOXIC AGENT; DILTIAZEM; DOXYCYCLINE; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NICARDIPINE; PHENYTOIN; PREDNISONE; PROTEINASE INHIBITOR; RAPAMYCIN; TACROLIMUS; THEOPHYLLINE; UNINDEXED DRUG;

BEHCET DISEASE; BONE DENSITY; BONE MARROW DEPRESSION; CANCER RISK; CARCINOGENESIS; CATARACT; CATARACTOGENESIS; CHORIORETINOPATHY; CLINICAL FEATURE; CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MONITORING; DRUG RESEARCH; DRUG SAFETY; ENZYME DEFECT; EYE INFECTION; GINGIVA HYPERPLASIA; GLUCOSE INTOLERANCE; HIRSUTISM; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPOMAGNESEMIA; IDIOPATHIC DISEASE; INSOMNIA; INTERMEDIATE UVEITIS; INTRAOCULAR HYPERTENSION; LIVER; LIVER TOXICITY; MOLECULAR INTERACTION; MOOD DISORDER; MUSCLE ATROPHY; NEPHROTOXICITY; NONHUMAN; PARESTHESIA; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SKIN TINGLING; STOMACH ULCER; TREATMENT OUTCOME; TREMOR; UVEITIS; WOUND HEALING IMPAIRMENT;

EID: 1642331531     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2004.01.003     Document Type: Article

References (40)

1. Borel J.F., Feurer C., Gubler H.U., et al. Biological effects of cyclosporin A a new antilymphocytic agent. Agents Actions. 6:1976;468.
2. Dick A.D., Azim M., Forrester J.V. Immunosuppressive therapy for chronic uveitis optimising therapy with steroids and cyclosporin A. Br J Ophthalmol. 81:1997;1107.
3. McCluskey P.J., Towler H.M., Lightman S. Management of chronic uveitis. BMJ. 320:2000;555.
4. Rothova A., Suttorp-van Schulten M.S., Frits Treffers W., et al. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol. 80:1996;332.
5. Suttorp-Schulten M.S., Rothova A. The possible impact of uveitis in blindness a literature survey. Br J Ophthalmol. 80:1996;844.
6. Caspi R.R. Immune mechanisms in uveitis. Springer Semin Immunopathol. 21:1999;113.
7. Matsuda S., Koyasu S. Mechanisms of action of cyclosporine. Immunopharmacology. 47:2000;119.
8. Nussenblatt R.B., Rodrigues M.M., Wacker W.B., et al. Cyclosporin A. Inhibition of experimental autoimmune uveitis in Lewis rats. J Clin Invest. 67:1981;1228.
9. Nussenblatt R.B., Rodrigues M.M., Salinas-Carmona M.C., et al. Modulation of experimental autoimmune uveitis with cyclosporin A. Arch Ophthalmol. 100:1982;1146.
10. Nussenblatt R.B., Palestine A.G., Rook A.H., et al. Treatment of intraocular inflammatory disease with cyclosporin A. Lancet. 2:1983;235.
11. Nussenblatt R.B., Palestine A.G., Chan C.C. Cyclosporin A therapy in the treatment of intraocular inflammatory disease resistant to systemic corticosteroids and cytotoxic agents. Am J Ophthalmol. 96:1983;275.
12. Binder A.I., Graham E.M., Sanders M.D., et al. Cyclosporin A in the treatment of severe Behcet's uveitis. Br J Rheumatol. 26:1987;285.
13. Le Hoang P., Girard B., Deray G., et al. Cyclosporine in the treatment of birdshot retinochoroidopathy. Transplant Proc. 20:1988;128.
14. BenEzra D., Cohen E., Chajek T., et al. Evaluation of conventional therapy versus cyclosporine A in Behcet's syndrome. Transplant Proc. 20:1988;136.
15. Masuda K., Nakajima A., Urayama A., et al. Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behcet's disease. Lancet. 1:1989;1093.
16. de Vries J., Baarsma G.S., Zaal M.J., et al. Cyclosporin in the treatment of severe chronic idiopathic uveitis. Br J Ophthalmol. 74:1990;344.
17. Nussenblatt R.B., Palestine A.G., Chan C.C., et al. Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis. Am J Ophthalmol. 112:1991;138.
18. Myers B.D., Ross J., Newton L., et al. Cyclosporine-associated chronic nephropathy. N Engl J Med. 311:1984;699.
19. McNally P.G., Feehally J. Pathophysiology of cyclosporin A nephrotoxicity experimental and clinical observations. Nephrol Dial Transplant. 7:1992;791.
20. Morales J.M., Andres A., Rengel M., et al. Influence of cyclosporin, tacrolimus and rapamycin on renal function and arterial hypertension after renal transplantation. Nephrol Dial Transplant. 16:(Suppl 1):2001;121.
21. Palestine A.G., Austin H.A. 3rd, Balow J.E., et al. Renal histopathologic alterations in patients treated with cyclosporine for uveitis. N Engl J Med. 314:1986;1293.
22. Towler H.M., Cliffe A.M., Whiting P.H., et al. Low dose cyclosporin A therapy in chronic posterior uveitis. Eye. 3:1989;282.
23. Towler H.M., Whiting P.H., Forrester J.V. Combination low dose cyclosporin A and steroid therapy in chronic intraocular inflammation. Eye. 4:1990;514.
24. Hooper P.L., Kaplan H.J. Triple agent immunosuppression in serpiginous choroiditis. Ophthalmology. 98:1991;944. (discussion 951-2).
25. Whitcup S.M., Salvo E.C. Jr, Nussenblatt R.B. Combined cyclosporine and corticosteroid therapy for sight-threatening uveitis in Behcet's disease. Am J Ophthalmol. 118:1994;39.
26. Vitale A.T., Rodriguez A., Foster C.S. Low-dose cyclosporine therapy in the treatment of birdshot retinochoroidopathy. Ophthalmology. 101:1994;822.
27. Vitale A.T., Rodriguez A., Foster C.S. Low-dose cyclosporin A therapy in treating chronic, noninfectious uveitis. Ophthalmology. 103:1996;365. (discussion 373-4).
28. Özdal P.C., Ortac S., Taskintuna I., et al. Long-term therapy with low dose cyclosporin A in ocular Behcet's disease. Doc Ophthalmol. 105:2002;301.
29. Walton R.C., Nussenblatt R.B., Whitcup S.M. Cyclosporine therapy for severe sight-threatening uveitis in children and adolescents. Ophthalmology. 105:1998;2028.
30. Kilmartin D.J., Forrester J.V., Dick A.D. Cyclosporin A therapy in refractory non-infectious childhood uveitis. Br J Ophthalmol. 82:1998;737.
31. Isnard Bagnis C., Tezenas Du Montcel S., Beaufils H., et al. Long-term renal effects of low-dose cyclosporine in uveitis-treated patients follow-up study. J Am Soc Nephrol. 13:2002;2962.
32. Klupp J., Holt D.W., van Gelder T. How pharmacokinetic and pharmacodynamic drug monitoring can improve outcome in solid organ transplant recipients. Transpl Immunol. 9:2002;211.
33. Kahan B.D. Individualization of cyclosporine therapy using pharmacokinetic and pharmacodynamic parameters. Transplantation. 40:1985;457.
34. Rocha G., Deschenes J., Cantarovich M. Cyclosporine monitoring with levels 6 hours after the morning dose in patients with noninfectious uveitis. Ophthalmology. 104:1997;245.
35. Martin D.F., DeBarge L.R., Nussenblatt R.B., et al. Synergistic effect of rapamycin and cyclosporin A in the treatment of experimental autoimmune uveoretinitis. J Immunol. 154:1995;922.
36. Sloper C.M., Powell R.J., Dua H.S. Tacrolimus (FK506) in the treatment of posterior uveitis refractory to cyclosporine. Ophthalmology. 106:1999;723.
37. Nussenblatt R.B., Fortin E., Schiffman R., et al. Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb a phase I/II clinical trial. Proc Natl Acad Sci U S A. 96:1999;7462.
38. Reiff A., Takei S., Sadeghi S., et al. Etanercept therapy in children with treatment-resistant uveitis. Arthritis Rheum. 44:2001;1411.
39. Sfikakis P.P., Theodossiadis P.G., Katsiari C.G., et al. Effect of infliximab on sight-threatening panuveitis in Behcet's disease. Lancet. 358:2001;295.
40. Joseph A., Raj D., Dua H.S., et al. Infliximab in the treatment of refractory posterior uveitis. Ophthalmology. 110:2003;1449.